IGC Pharma Inc Dossier - Source-backed chat

IGC Pharma Inc

IGCNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.65

Intrinsic Value $0.36median of 2 methodsbased on filings through 30 Jun 2026

Market Price $0.27Price as of 1 Oct 2026

UndervaluedIntrinsic value is 33% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $27.9M

Enterprise Value $27.7M

Shares Outstanding 103.4M diluted

Next Earnings Date18 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

IGC Pharma is a high-risk, high-reward clinical-stage biotechnology company transitioning into a pure-play Alzheimer's therapeutics developer. The investment thesis centers on its lead asset, IGC-AD1, a low-dose cannabinoid-based formulation targeting agitation in Alzheimer's dementia. Having reached its full enrollment target of 146 patients in the Phase 2 CALMA trial in June 2026, the company is poised for a major clinical catalyst with upcoming topline data. While the company faces severe near-term liquidity constraints, its $12 million credit facility and the potential for non-dilutive grants or strategic partnerships provide a bridge to clinical readouts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$4.25

High · most bullish analyst$5.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.2515%

The CALMA trial fails to show statistical significance in reducing agitation compared to placebo, or safety concerns emerge regarding the low-dose THC formulation in elderly patients. Depleted cash reserves force highly dilutive equity financing or a restructuring of operations.

Base CaseCentral scenario

$4.2550%

Matches the consensus mean

The CALMA trial meets its primary safety endpoints and shows positive trends in efficacy, supporting progression to Phase 3. The company utilizes its O-Bank credit facility and moderate equity issuance to fund operations, while slowly commercializing its MINT-AD AI platform to generate supplementary revenue.

Bull CaseUpside scenario

$5.5035%

The Phase 2 CALMA trial delivers strong, statistically significant efficacy data showing a marked reduction in agitation and sleep disturbances with a clean safety profile. This triggers a lucrative licensing partnership with a major biopharmaceutical firm, validating IGC's AI-driven drug discovery platform and funding Phase 3 development without diluting existing shareholders.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Lead asset IGC-AD1 has completed its 146-patient enrollment target, paving the way for near-term topline Phase 2 data catalysts.
Addresses a massive unmet medical need in Alzheimer's agitation, a market currently dominated by atypical antipsychotics with harsh black-box warnings.
Integration of proprietary AI platforms (MINT-AD and AHA) to accelerate trial design, patient stratification, and drug discovery.
Strong analyst backing with a consensus 'Strong Buy' rating and price targets representing substantial upside from current sub-dollar levels.

Key Investment Risks

Severe liquidity risk with cash and cash equivalents of only $207,000 as of March 31, 2026, necessitating immediate capital raises or credit drawdowns.
High clinical development risk inherent to Alzheimer's disease therapeutics, where historical failure rates are exceptionally high.
Regulatory hurdles surrounding cannabinoid-based therapies and evolving FDA guidelines on hemp- and cannabis-derived compounds.

Thesis Invalidation Triggers

Failure of IGC-AD1 to meet primary efficacy endpoints in the Phase 2 CALMA trial.
Inability to extend or draw down on the $12 million O-Bank credit facility, leading to a severe going-concern crisis.
Severe adverse safety events reported in the CALMA trial cohort.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.